Evidence map›Paper›PMID 40921766›Full record

ArticleJournal of human genetics2026

Augmenting cost-effectiveness in clinical diagnosis using extended whole-exome sequencing: SNVs, SVs, and beyond.

Fuyuki Miya, Daisuke Nakato, Hisato Suzuki, Mamiko Yamada, Daisuke Watanabe, Toshiki Takenouchi, Kenjiro Kosaki

Abstract read
In one paragraph

Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fuyuki MiyaCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan. fmiya@keio.jp.ORCID http://orcid.org/0000-0001-6758-2015
Daisuke NakatoCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.
Hisato SuzukiCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8122-7180
Mamiko YamadaCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.
Daisuke WatanabeDepartment of Pediatrics, Yamanashi University, Yamanashi, Japan.
Toshiki TakenouchiDepartment of Child Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kenjiro KosakiCenter for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development (AMED) JP24ek0109549Japan Agency for Medical Research and Development (AMED) JP24ek0109672MEXT | Japan Society for the Promotion of Science (JSPS) 24K14705
6 · The paper itself

Abstract

In standard short-read whole-exome sequencing (WES), capture probes are typically designed to target the protein-coding regions (CDS), and regions outside the exons-except for adjacent intronic sequences-are rarely sequenced. Although the majority of known pathogenic variants reside within the CDS as nonsynonymous variants, some disease-causing variants are located in regions that are difficult to detect by WES alone, such as deep intronic variants and structural variants, often requiring whole-genome sequencing (WGS) for detection. Moreover, WES has limitations in reliably identifying pathogenic variants within mitochondrial DNA or repetitive regions. Here, we propose a strategy to improve the diagnostic yield in a cost-effective manner by expanding the target design of WES beyond the CDS. As an illustrative example, we experimentally validated an extended WES approach covering intronic and untranslated regions (UTRs) of 188 genes listed in the Japanese public health insurance-covered multiple gene testing, intronic and UTRs of 81 genes listed in ACMG Secondary Findings (SF) v3.2, and 70 repeat regions associated with diseases. Additionally, the entire mitochondrial genome was targeted. We demonstrate the coverage of these extended regions based on experimental data and present case examples in which previously diagnosed pathogenic variants located outside the CDS were successfully detected using this approach. This strategy enables a substantial increase in the chance of achieving a definitive diagnosis for patients using WES alone, without requiring WGS, at a cost comparable to conventional WES. Our method has the potential to significantly shorten the diagnostic odyssey and represents a valuable approach in clinical genomics.

Indexed as

Cost-Benefit AnalysisExome SequencingGenetic TestingPolymorphism, Single NucleotideDNA, MitochondrialGenome, MitochondrialHumansIntronsDNA, Mitochondrial

Identifiers

PMID40921766
PMCPMC12689423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.